Design,Synthesis, and Docking Studies of Novel Dimethyl Triazene Incorporated Thiazolyl Pyrazolines for Anticancer Activity

A novel series of dimethyl triazene incorporated thiazolyl pyrazolines have been designed on the basis of hybridization and also in support with combi‐targeting approach. The designed compounds were synthesized through facile synthetic methods, and the compounds were confirmed by ¹H NMR, ¹³C NMR, MS, and elemental analysis. Further, compounds were screened for in vitro anticancer activity against human breast cancer (MCF‐7) and human colon cancer (HT‐29) cell lines by MTT assay. Among all the tested compounds, compound 9b showed highest activity against both the cell lines in comparison with reference drug, Cisplatin. In addition, the synthesized compounds were docked into VEGFR‐2 kinase (PDB code: 2XIR) to explore their binding interactions at the active site. The compounds showed essential key interactions as that of known VEGFR‐2 inhibitors, and hence, the synthesized compounds may be considered as molecular scaffolds for anticancer activity.